Back to School: How biopharma can reboot drug development. Access exclusive analysis here

KRN5500: Phase IIa data

Data from a double-blind, dose-escalation, U.S. Phase IIa trial in 19 cancer patients showed that KRN5500

Read the full 168 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE